Search results for "Azine"

showing 10 items of 1589 documents

Mechanism of New Antipsychotic Medications

2003

Antagonism of D 2 -like dopamine receptors is the putative mechanism underlying the antipsychotic efficacy of psychotropic drugs. Positron emission tomographic studies suggest that the antipsychotic effect of dopamine receptor antagonists occurs within a therapeutic window between 60% and 80%(striatal) D 2 receptor occupancy. The incidence of extrapyramidal side effects increases above the 80% threshold. However, the novel atypical antipsychotic drug, aripiprazole, occupies up to 95% of striatal D 2 -like dopamine receptors at clinical doses, and the incidence of extrapyramidal side effects with aripiprazole is no higher than with placebo. The most likely explanation for this finding is ari…

medicine.medical_specialtyPsychosismedicine.drug_classmedicine.medical_treatmentAripiprazoleAtypical antipsychoticQuinolonesPharmacologyPartial agonistPiperazinesBasal Ganglia DiseasesArts and Humanities (miscellaneous)Dopamine receptor D2Internal medicinemedicineHumansAntipsychoticDose-Response Relationship DrugReceptors Dopamine D2Putamenmedicine.diseaseCorpus StriatumProlactinDopamine D2 Receptor AntagonistsPsychiatry and Mental healthEndocrinologyMechanism of actionDopamine receptorSchizophreniaAripiprazolemedicine.symptomPsychologyAntipsychotic AgentsTomography Emission-Computedmedicine.drugArchives of General Psychiatry
researchProduct

Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis.

1990

Recent studies have established the clinical efficacy of S-adenosyl-L-methionine (SAMe) in the treatment of cholestasis associated with hepatic diseases, pregnancy and the administration of estrogen-containing oral contraceptives. In 4 clinical trials involving a total of 639 patients with cholestasis due to acute or chronic liver disease, SAMe in an intravenous dose of 800 mg/day or an oral regimen of 1.6 g/day for 2 weeks was superior to placebo in relieving the symptom of pruritus and in restoring serum total bilirubin and serum alkaline phosphatase towards normal. The drug is also effective in intrahepatic cholestasis of pregnancy (ICP), with intravenous administration of 800 mg/day for…

medicine.medical_specialtyS-Adenosylmethioninemedicine.drug_classmedicine.medical_treatmentCholestasis IntrahepaticPharmacologyChronic liver diseasePlaceboBile Acids and SaltsCholestasisPregnancyInternal medicinemedicineAnimalsHumansPharmacology (medical)ChlorpromazineChemotherapybusiness.industryBilirubinmedicine.diseasePregnancy ComplicationsEndocrinologymedicine.anatomical_structure1-NaphthylisothiocyanateEstrogenHepatocyteFemalebusinessCholestasis of pregnancymedicine.drugDrugs
researchProduct

Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway function.

2009

The impact of serotonergic neurotransmission on brain dopaminergic pathways has substantial relevance to many neuropsychiatric disorders. A particularly prominent role has been ascribed to the inhibitory effects of serotonin 2C receptor (5-HT2CR) activation on physiology and behavior mediated by the mesolimbic dopaminergic pathway, particularly in the terminal region of the nucleus accumbens. The influence of this receptor subtype on functions mediated by the nigrostriatal dopaminergic pathway is less clear. Here we report that a null mutation eliminating expression of 5-HT2CRs produces marked alterations in the activity and functional output of this pathway. 5-HT2CR mutant mice displayed i…

medicine.medical_specialtySerotoninDopamineDopamine AgentsPhysiologySubstantia nigraStriatumBiologySettore BIO/09 - FisiologiaPiperazinesArticleMiceDopamine receptor D1Dopamine Uptake InhibitorsDopamineDopamine receptor D2Internal medicineNeural PathwaysmedicineReceptor Serotonin 5-HT2CAnimalsNeuronsBehavior AnimalPars compactaGeneral Neuroscience5-HT2CR substantia nigra pars compacta dorsal striatum dopamine extracellular recording in vivo patch clamp recording microdialysis Locomotor activity Stereotypic behaviorDopaminergicNeurobehavioral disordersBenzazepinesGroomingCorpus StriatumElectrophysiologyMice Inbred C57BLSubstantia NigraAmphetamineEndocrinologymedicine.anatomical_structureDopaminergic pathwaysDopamine AgonistsMutationAutoradiographyStereotyped BehaviorNeuroscienceLocomotionmedicine.drugThe Journal of neuroscience : the official journal of the Society for Neuroscience
researchProduct

Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?

2010

5-Amino-salacylic acid (5-ASA) is up to now the treatment of choice in the induction and maintenance of remission of mild-to-moderate ulcerative colitis (UC). Sulfasalazine, despite similar efficacy, is hampered by more side effects, but in presence of peripheral arthopaties it remains the treatment of choice. The new delayed release MMX formulation seems to be promising in reducing compliance problems, but further studies are warranted to show the superiority of new MMX formulation compared with the older formulations of 5-ASA. Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to ther…

medicine.medical_specialtySettore MED/09 - Medicina InternaClinical BiochemistryPharmacologyPlaceboSulfasalazineInternal medicineDrug DiscoverymedicineHumansDosingColitisMesalamine5-ASA Treatment Choice Ulcerative ColitisPharmacologyClinical Trials as Topicbusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseUlcerative colitisTacrolimusRegimenMolecular MedicineColitis UlcerativeRosiglitazonebusinessmedicine.drugCurrent Drug Targets
researchProduct

BENEFICIAL EFFECT OF PROBIOTICS ADMINISTRATION IN INFLAMMATORY BOWEL DISEASE AND RELATED SPONDYLOARTHROPATHY: A PROSPECTIVE STUDY

2015

Background: Therapeutic treatment for inflammatory bowel disease (IBD) may follow different approaches, systemic as well as local, especially when the target is the osteoarticular apparatus. Although some clinical trials have suggested benefits from probiotics administration in IBD, there is still a great deal of controversy on their use. The aim of this study was to further investigate the effects of probiotics in patients with IBD and related spondyloarthropathy. Material/Methods: Fifty-nine patients affected by IBD with extra-intestinal involvement where evaluated from 2006 to 2010. Twenty-eight patients received administration of a standard therapy with mesalazine and 31 where treated w…

medicine.medical_specialtySettore MED/09 - Medicina InternaSpondyloarthropathyBiomedical EngineeringBioengineeringInflammatory bowel diseaseGastroenterologylaw.inventionchemistry.chemical_compoundProbioticMesalazineRandomized controlled triallawInternal medicinemedicineIn patientProspective cohort studyGeneral PsychologyInflammatory Bowel Disease IBD Microbiome Dysbiosis MALTbusiness.industrySettore BIO/16 - Anatomia UmanaGeneral Medicinemedicine.diseaseClinical trialSettore MED/18 - Chirurgia Generalechemistrybusiness
researchProduct

Model-specific effects of bumetanide on epileptiform activity in the in-vitro intact hippocampus of the newborn mouse.

2007

The immature brain has a higher susceptibility to develop seizures, which often respond poorly to classical pharmacological treatment. It has been recently suggested that bumetanide, which blocks Na(+)-dependent K(+)-Cl(-)-cotransporter isoform 1 (NKCC1) and thus attenuates depolarizing GABAergic responses, could soothe epileptiform activity in immature nervous systems. To evaluate whether bumetanide consistently attenuates epileptiform activity, we investigated the effect of 10 microM bumetanide in five different in-vitro epilepsy models using field potential recordings in the CA3 region of intact mouse hippocampal preparations at postnatal day 4-7. Bumetanide reduced amplitude and frequen…

medicine.medical_specialtySodium-Potassium-Chloride SymportersHippocampusKainate receptorHippocampal formationIn Vitro TechniquesHippocampusMembrane PotentialsCellular and Molecular Neurosciencechemistry.chemical_compoundEpilepsyMiceChloride ChannelsInternal medicinemedicineAnimalsSolute Carrier Family 12 Member 2MagnesiumBumetanidePharmacologyEpilepsyDepolarizationStrychninemedicine.diseaseDisease Models AnimalEndocrinologychemistryAnimals NewbornGabazinePotassiumBumetanidemedicine.drugNeuropharmacology
researchProduct

The interferance of muscarinic receptors with the noradrenaline release from sympathetic nerve endings caused by nicotinic agents.

1968

medicine.medical_specialtySympathetic nervous systemSympathetic Nervous SystemReceptors DrugIn Vitro TechniquesPiperazinesNorepinephrineInternal medicineMuscarinic acetylcholine receptorMuscarinic acetylcholine receptor M4medicineAnimalsSympathomimeticsPharmacologyNerve EndingsChemistryMyocardiumMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2General MedicineMuscarinic acetylcholine receptor M1AcetylcholinePerfusionEndocrinologymedicine.anatomical_structureRabbitsFree nerve endingAcetylcholinemedicine.drugNaunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie
researchProduct

Corticotropin-Releasing Hormone-Mediated Induction of Intracellular Signaling Pathways and Brain-Derived Neurotrophic Factor Expression Is Inhibited …

2005

CRH receptor (CRHR) 1 and the cannabinoid receptor 1 (CB1) are both G protein-coupled receptors. Activation of CRHR1 leadstoincreasesincAMPproductionandphosphorylationof the transcription factor cAMP response element-binding protein (CREB). In contrast, CB1 is negatively coupled to the cAMP signaling cascade. In this study, we analyzed a putative interaction between these two systems focusing on the regulation of the expression of brain-derived neurotrophic factor (BDNF), a CREB-regulated gene. In situ hybridization revealed coexpression of CRHR1 and CB1 receptors in the granular layer of the cerebellum. Therefore, we analyzed the effects of CRH and the CB1 agonist WIN-55,212-2 on BDNF expr…

medicine.medical_specialtyTime FactorsCorticotropin-Releasing HormoneMorpholinesmedicine.medical_treatmentImmunoblottingEnzyme-Linked Immunosorbent AssayTropomyosin receptor kinase BNaphthalenesCREBModels BiologicalRats Sprague-DawleyMiceEndocrinologyNeurotrophic factorsCerebellumInternal medicineCannabinoid Receptor ModulatorsCyclic AMPmedicineAnimalsRNA MessengerCyclic AMP Response Element-Binding ProteinReceptorEgtazic AcidCells CulturedIn Situ HybridizationNeuronsBrain-derived neurotrophic factorSulfonamidesbiologyReverse Transcriptase Polymerase Chain ReactionBrain-Derived Neurotrophic FactorCalcium Channel BlockersIsoquinolinesEndocannabinoid systemBenzoxazinesRatsMice Inbred C57BLPyrimidinesEndocrinologynervous systembiology.proteinCalciumCannabinoidSignal transductionEndocannabinoidsProtein BindingSignal TransductionEndocrinology
researchProduct

Intrinsic activation of GABAA receptors suppresses epileptiform activity in the cerebral cortex of immature mice

2010

SUMMARY Purpose: Activation of ionotropic c-aminobutyric acid type A (GABAA) receptors induces in immature neocortical neurons a membrane depolarization that may contribute to the higher epilepsy susceptibility in newborns. To elucidate whether depolarizing GABAergic responses enhance or attenuate epileptiform activity in the immature neocortex, we investigated the effect of agonists, antagonists, and positive modulators of GABAA receptors on epileptiform activity. Methods: We performed in vitro field potential recordings on isolated whole neocortex preparations and whole cell recordings of identified pyramidal neurons in 400-lm slices of immature (postnatal day 1–7) mice. Epileptiform acti…

medicine.medical_specialtyZolpidemNeocortexbiologyGABAA receptormusculoskeletal neural and ocular physiologynervous system diseaseschemistry.chemical_compoundEndocrinologymedicine.anatomical_structurenervous systemNeurologychemistryInternal medicinemedicinebiology.proteinGabazineGABA transporterGABAergicNeurology (clinical)PicrotoxinIonotropic effectmedicine.drugEpilepsia
researchProduct

Ranolazine induced modifications of ventricular fibrillation activation complexity under mechanical stretch

2013

medicine.medical_specialtybusiness.industryRanolazineCardiac arrhythmiamedicine.diseasemedicine.anatomical_structureInternal medicineVentricular fibrillationCardiologyMyocyteMedicineAtrium (heart)Cardiology and Cardiovascular MedicinebusinessPerfusionmedicine.drugEuropean Heart Journal
researchProduct